Literature DB >> 28552256

Management of acute exacerbations of chronic obstructive pulmonary disease (COPD). Guidelines from the Société de pneumologie de langue française (summary).

S Jouneau1, M Dres2, A Guerder3, N Bele4, A Bellocq5, A Bernady6, G Berne7, A Bourdin8, G Brinchault9, P R Burgel10, N Carlier11, F Chabot12, J M Chavaillon13, J Cittee6, Y E Claessens14, B Delclaux15, G Deslée16, A Ferré17, A Gacouin18, C Girault19, C Ghasarossian20, P Gouilly21, C Gut-Gobert22, J Gonzalez-Bermejo23, G Jebrak24, F Le Guillou25, G Léveiller26, A Lorenzo27, H Mal28, N Molinari29, H Morel30, V Morel31, F Noel32, H Pégliasco33, J M Perotin16, J Piquet34, S Pontier35, A Rabbat36, M Revest37, G Reychler38, S Stelianides39, P Surpas40, P Tattevin37, N Roche41.   

Abstract

Chronic obstructive pulmonary disease (COPD) is the chronic respiratory disease with the most important burden on public health in terms of morbidity, mortality and health costs. For patients, COPD is a major source of disability because of dyspnea, restriction in daily activities, exacerbation, risk of chronic respiratory failure and extra-respiratory systemic organ disorders. The previous French Language Respiratory Society (SPLF) guidelines on COPD exacerbations were published in 2003. Using the GRADE methodology, the present document reviews the current knowledge on COPD exacerbation through 4 specific outlines: (1) epidemiology, (2) clinical evaluation, (3) therapeutic management and (4) prevention. Specific aspects of outpatients and inpatients care are discussed, especially regarding assessment of exacerbation severity and pharmacological approach.
Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bronchodilatateurs; Bronchodilators; Bronchopneumopathie chronique obstructive; COPD exacerbation; Chronic obstructive pulmonary disease; Corticosteroids; Corticostéroïdes; Exacerbation de la BPCO; Healthcare management; Organisation des soins

Mesh:

Year:  2017        PMID: 28552256     DOI: 10.1016/j.rmr.2017.03.034

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  6 in total

1.  Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study.

Authors:  Carey Meredith Suehs; Maéva Zysman; Cécile Chenivesse; Pierre-Régis Burgel; F Couturaud; Gaëtan Deslee; Patrick Berger; Chantal Raherison; Gilles Devouassoux; Christophe Brousse; Nicolas Roche; Mathieu Molimard; Thierry Chinet; Philippe Devillier; Pascal Chanez; Romain Kessler; Alain Didier; Yan Martinat; Olivier Le Rouzic; A Bourdin
Journal:  BMJ Open       Date:  2020-07-01       Impact factor: 2.692

2.  Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges.

Authors:  G Deslée; M Zysman; P-R Burgel; T Perez; L Boyer; J Gonzalez; N Roche
Journal:  Respir Med Res       Date:  2020-05-11

Review 3.  Telemedicine for Pre-Employment Medical Examinations and Follow-Up Visits on Board Ships: A Narrative Review on the Feasibility.

Authors:  Getu Gamo Sagaro; Marzio Di Canio; Emanuele Talevi; Francesco Amenta
Journal:  Healthcare (Basel)       Date:  2021-01-13

4.  Management of acute COPD exacerbations in France: A qualitative survey in a private practice setting.

Authors:  Anne Compagnon; Laurent Nguyen; Zeina Antoun; Bruno Stach; Christophe Zanetti; Frédéric Le Guillou
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

5.  Early antibiotic therapy is associated with a lower probability of successful liberation from mechanical ventilation in patients with severe acute exacerbation of chronic obstructive pulmonary disease.

Authors:  G Deniel; M Cour; L Argaud; J C Richard; L Bitker
Journal:  Ann Intensive Care       Date:  2022-09-24       Impact factor: 10.318

6.  [Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].

Authors:  J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán
Journal:  Rev Esp Quimioter       Date:  2018-10-04       Impact factor: 1.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.